Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Treatment with erenumab was associated with improved health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine, according to a study published in Neurology.
In this study, a total of 667 patients with chronic migraine were randomly assigned 3:2:2 to receive placebo, erenumab 70 mg, or erenumab 140 mg monthly. Exploratory end points included migraine-specific HRQoL (assessed with the Migraine-Specific Quality-of-Life Questionnaire [MSQ]; 0-100 range), headache impact (evaluated with the Headache Impact Test-6 [HIT-6]), migraine-related disability (assessed with the Migraine Disability Assessment [MIDAS] test; 36 to 78 range), and pain interference (evaluated with the Patient-Reported Outcomes Measurements Information System [PROMIS] Pain Interference Scale short form 6b; 41 to 78.3 range).
After 3 months, participants who had received erenumab 70 mg or 140 mg vs placebo reported greater increases in all 3 MSQ domains. Participants receiving erenumab 70 mg had mean changes from baseline of 17.7 in MSQ-role function restrictive (RFR), 13.0 in MSQ-role function preventative (RFP), and 18.2 in MSQ-emotional function (EF). Participants receiving erenumab 140 mg had mean changes from baseline of 19.1 in MSQ-RFR, 13.8 in MSQ-RFP, and 18.8 in MSQ-EF. In participants receivingplacebo, these changes were 11.8, 8.9, and 9.9, respectively.
Participants in both erenumab groups experienced a −5.6 change in HIT-6 scores from baseline to 3 months compared with a −3.1 change in participants receiving placebo. At month 3, MIDAS scores improved by −19.4 days in the erenumab 70 mg group, −19.8 days in the erenumab 140 mg group, and −7.5 days in the placebo group.
“Overall, these results demonstrate that erenumab led to sustained, significant improvements that are consistent across multiple measures of HRQoL, social and psychological effect, and disability in patients with [chronic migraine],” the researchers noted.
Disclosures
This study was fully funded by Amgen. Erenumab is co-developed in partnership with Amgen and Novartis.
Reference
Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. [published online April 17, 2019]. Neurology. doi:10.1212/WNL.0000000000007452
